Pfizer Receives 6-Month Patent Extension for Lyrica

Drug company Pfizer has received a six-month patent extension for Lyrica, a non-opioid medication used to treat pain and a top drug in workers’ comp. The extension from the U.S. Food and Drug Administration gives Pfizer an additional six months of market exclusivity — through June 30, 2019, the company announced Tuesday. The Lyrica patent had been set to expire at the end of the year, which would have opened the door to less-expensive generic alternatives. The extension of Lyrica’s market exclusivity comes after Pfizer announced this month that it would raise...